Skip to content

Annexon

US · ANNX #3455 by market cap Listed 2020
3.94 -0.08 -1.87%
Live - 5344 symbols - heartbeat 74s ago · 2026-10-08 10:00
Pre-market 4.11 +2.49%
After-hours 4.05 +1.00%
Overnight 4.05 +1.00%
Market cap
745.99M
P/B
4.01
EPS
-1.34
Reader sentiment Are you bullish or bearish on ANNX?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 4.09 Expensive vs history 85th percentile
5-year average 1.94 · #352 of 513 in Biotechnology
P/E ratio -3.55 In line with history 34th percentile
5-year average -2.93 · forward -3.28
P/S ratio --
5-year average 0.00 · forward 69.67

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Annexon (ANNX) 745.99M -3.48 4.01 0.00%
Vertex Pharmaceuticals (VRTX) 127.62B 29.32 6.30 0.00%
Moderna (MRNA) 78.01B -24.48 11.54 0.00%
Regeneron Pharmaceuticals (REGN) 75.28B 18.09 2.37 0.50%
argenx SE (ARGX) 50.75B 30.74 6.03 0.00%
Revolution Medicines (RVMD) 39.32B -20.68 15.09 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value4.41 Economic moatNone UncertaintyVery High

Trading 12.0% below Morningstar's fair value estimate.

Fair value

Annexon Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $4.41 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's balance sheet strengthens our estimated fair value. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 5.5 ranks in the top 20% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.8, a core component of valuation, lies in the bottom 20% compared with global peers. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 10:00:14 · For reference only, not investment advice and not tailored to your situation.